DGAP-News: Novavax, Inc. /
Novavax Appoints Sven Andreasson as Senior Vice President, Corporate
Development
06.05.2014 / 22:30
---------------------------------------------------------------------
GAITHERSBURG, Md., 2014-05-06 22:30 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused
on the discovery, development and commercialization of recombinant nanoparticle
vaccines and adjuvants, today announced the appointment of Sven Andreasson to
the position of Senior Vice President, Corporate Development, effective June 2,
2014. Mr. Andreasson will be responsible for identifying, prioritizing and
evaluating new strategic opportunities that leverage the company's core
strengths and growth initiatives.
Mr. Andreasson brings to Novavax a long history of experience in
biopharmaceutical operations, executive management and strategic development
from his many years in the industry. From 2012 to 2013 he served as the Chief
Executive Officer of Isconova AB in Uppsala, Sweden, a leading international
vaccine adjuvant company acquired by Novavax in 2013, currently operating as
Novavax AB. Prior to his role at Isconova AB, Mr. Andreasson served as the
Chief Executive Officer of Beta-Cell NV in Brussels, Belgium from 2008 to 2012
and as Chief Executive Officer of Active Biotech AB in Lund, Sweden from 1999
to 2008. Mr. Andreasson spent a number of years in roles inside Pharmacia
Corporation including: President of Pharmacia SA, France, President of
KabiPharmacia International and President of Pharmacia Arzneimittel GmbH,
Germany.
'My first serious interactions with Sven occurred during our negotiations to
acquire Isconova AB. I was immediately impressed with him as a pragmatic and
thoughtful business professional. It became readily apparent to me that Novavax
would benefit from his extensive vaccine and pharmaceutical industry experience
and insight,' said Stan Erck, President and CEO of Novavax. 'I am very excited
to have someone with Sven's experience help me and the entire management team
to evaluate organic and non-organic opportunities to build this business and
increase shareholder value.'
Mr. Andreasson stated, 'Novavax has an impressive pipeline and a remarkably
talented and experienced team of professionals. Novavax' successful clinical
trial data over recent months underscore its potential to develop into a major
vaccine player. With today's strong platform as a base, we will systematically
evaluate promising new growth possibilities. I look forward to joining the team
of Novavax.'
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant
nanoparticle vaccine technology, the company produces vaccine candidates to
efficiently and effectively respond to both known and newly emergent diseases.
Additional information about Novavax is available on the company's website,
novavax.com.
Forward-Looking Statements
Statements herein relating to the future of Novavax and the ongoing development
of its vaccine and adjuvant products are forward-looking statements. Novavax
cautions that these forward looking statements are subject to numerous risks
and uncertainties, which could cause actual results to differ materially from
those expressed or implied by such statements. These risks and uncertainties
include those identified under the heading 'Risk Factors' in the Novavax Annual
Report on Form 10-K for the year ended December 31, 2013, and filed with the
Securities and Exchange Commission (SEC). Investors are cautioned not to place
considerable reliance on the forward-looking statements contained in this press
release. You are encouraged to read company filings with the SEC, available at
sec.gov, for a discussion of these and other risks and uncertainties. The
forward-looking statements in this press release speak only as of the date of
this document, and the company undertakes no obligation to update or revise any
of the statements. The company's business is subject to substantial risks and
uncertainties, including those referenced above. Investors, potential
investors, and others should give careful consideration to these risks and
uncertainties.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
News Source: NASDAQ OMX
End of Corporate News
---------------------------------------------------------------------
06.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Novavax, Inc.
United States
ISIN: US6700021040
End of News DGAP News-Service
---------------------------------------------------------------------
266849 06.05.2014
DGAP-News: Novavax Appoints Sven Andreasson as Senior Vice President, Corporate Development
| Source: EQS Group AG